materials-logo

Journal Browser

Journal Browser

Modulation of Antibiotics and Anticancer Drugs Activity by Biocompatible Nanoparticles

A special issue of Materials (ISSN 1996-1944). This special issue belongs to the section "Biomaterials".

Deadline for manuscript submissions: closed (20 February 2022) | Viewed by 8182

Special Issue Editors


E-Mail Website
Guest Editor
Laboratory of Biophysics, Intercollegiate Faculty of Biotechnology University of Gdansk and Medical University of Gdansk, Abrahama 58, 80-307 Gdańsk, Poland
Interests: nanoparticles; drug activity; biologically active compounds; DNA binding; thermodynamical models; anticancer drugs; non-covalent interactions

E-Mail Website
Guest Editor
Taras Shevchenko National University of Kyiv, ESC "Institute of Biology and Medicine", Department of Biophysics and Medical Informatics, Ukraine
Interests: nanoparticles; anticancer drugs; non-covalent interactions; thermodynamical models; computer simulation

E-Mail
Guest Editor
Laboratory of Molecular and Cell Biophysics, Sevastopol State University, Sevastopol, Crimea
Interests: drug–nanoparticle interactions; thermodynamics of binding; models of binding; aggregation

Special Issue Information

Dear Colleagues,

Nowadays, the treatment of many common diseases is based on drug therapy. Commonly used classical antibiotics are still less and less effective because of the emergence of new drug-resistant bacterial strains. The development of new antibiotics is decreasing each year. Therefore, it has become very important to seek new approaches in the usage of existing classic antibiotics, to give them a second life.

On the other hand, anticancer drugs commonly used in chemotherapy are effective against cancer; however, they have many adverse side effects.

Therefore, the modulation of these drugs’ activity by biocompatible nanoparticles seems to be an interesting way to improve these drugs’ activity and decrease their possible side-effects. Biocompatible nanoparticles of various natures may act as drug carriers, modify cell membrane permeability, directly interact with drug molecules, modify drug biological activity, etc. Finally, all these effects or interactions may modulate these drugs’ activity and be used successfully in treatment in the near future.

The Special Issue will cover but will not be limited to the following topics:

  • The direct interaction between drugs and biocompatible nanoparticles;
  • Biocompatible nanoparticles as drug carriers;
  • Anticancer nanoparticle–drug effect in vitro and in vivo;
  • Improving classic antibiotics’ activity by biocompatible nanoparticles.

Prof. Jacek Piosik
Prof. Yuriy Prylutskyy
Prof. Maxim Evstigneev
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Materials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Antibiotics
  • Antineoplastic drugs
  • Nanoparticles
  • Drug activity modulation
  • Non-covalent interactions
  • Drug side effects
  • Drug resistance
  • Drug efficacy
  • Drug therapy

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2416 KiB  
Article
Nanocomplex of Berberine with C60 Fullerene Is a Potent Suppressor of Lewis Lung Carcinoma Cells Invasion In Vitro and Metastatic Activity In Vivo
by Iryna Horak, Svitlana Prylutska, Iryna Krysiuk, Serhii Luhovskyi, Oleksii Hrabovsky, Nina Tverdokhleb, Daria Franskevych, Dmytro Rumiantsev, Anton Senenko, Maxim Evstigneev, Liudmyla Drobot, Olga Matyshevska, Uwe Ritter, Jacek Piosik and Yuriy Prylutskyy
Materials 2021, 14(20), 6114; https://doi.org/10.3390/ma14206114 - 15 Oct 2021
Cited by 7 | Viewed by 1981
Abstract
Effective targeting of metastasis is considered the main problem in cancer therapy. The development of herbal alkaloid Berberine (Ber)-based anticancer drugs is limited due to Ber’ low effective concentration, poor membrane permeability, and short plasma half-life. To overcome these limitations, we used Ber [...] Read more.
Effective targeting of metastasis is considered the main problem in cancer therapy. The development of herbal alkaloid Berberine (Ber)-based anticancer drugs is limited due to Ber’ low effective concentration, poor membrane permeability, and short plasma half-life. To overcome these limitations, we used Ber noncovalently bound to C60 fullerene (C60). The complexation between C60 and Ber molecules was evidenced with computer simulation. The aim of the present study was to estimate the effect of the free Ber and C60-Ber nanocomplex in a low Ber equivalent concentration on Lewis lung carcinoma cells (LLC) invasion potential, expression of epithelial-to-mesenchymal transition (EMT) markers in vitro, and the ability of cancer cells to form distant lung metastases in vivo in a mice model of LLC. It was shown that in contrast to free Ber its nanocomplex with C60 demonstrated significantly higher efficiency to suppress invasion potential, to downregulate the level of EMT-inducing transcription factors SNAI1, ZEB1, and TWIST1, to unblock expression of epithelial marker E-cadherin, and to repress cancer stem cells-like markers. More importantly, a relatively low dose of C60-Ber nanocomplex was able to suppress lung metastasis in vivo. These findings indicated that сomplexation of natural alkaloid Ber with C60 can be used as an additional therapeutic strategy against aggressive lung cancer. Full article
Show Figures

Figure 1

13 pages, 15371 KiB  
Article
A New Water-Soluble Thermosensitive Star-Like Copolymer as a Promising Carrier of the Chemotherapeutic Drug Doxorubicin
by Mariia Chernykh, Dmytro Zavalny, Viktoriya Sokolova, Stanislav Ponomarenko, Svitlana Prylutska, Yuliia Kuziv, Vasyl Chumachenko, Andrii Marynin, Nataliya Kutsevol, Matthias Epple, Uwe Ritter, Jacek Piosik and Yuriy Prylutskyy
Materials 2021, 14(13), 3517; https://doi.org/10.3390/ma14133517 - 24 Jun 2021
Cited by 7 | Viewed by 2000
Abstract
A new water-soluble thermosensitive star-like copolymer, dextran-graft-poly-N-iso-propilacrylamide (D-g-PNIPAM), was created and characterized by various techniques (size-exclusion chromatography, differential scanning calorimetry, Fourier-transform infrared (FTIR) spectroscopy, and dynamic light scattering (DLS) spectroscopy). The viability of cancer cell lines (human transformed cervix epithelial cells, HeLa) as [...] Read more.
A new water-soluble thermosensitive star-like copolymer, dextran-graft-poly-N-iso-propilacrylamide (D-g-PNIPAM), was created and characterized by various techniques (size-exclusion chromatography, differential scanning calorimetry, Fourier-transform infrared (FTIR) spectroscopy, and dynamic light scattering (DLS) spectroscopy). The viability of cancer cell lines (human transformed cervix epithelial cells, HeLa) as a model for cancer cells was studied using MTT and Live/Dead assays after incubation with a D-g-PNIPAM copolymer as a carrier for the drug doxorubicin (Dox) as well as a D-g-PNIPAM + Dox mixture as a function of the concentration. FTIR spectroscopy clearly indicated the complex formation of Dox with the D-g-PNIPAM copolymer. The size distribution of particles in Hank’s solution was determined by the DLS technique at different temperatures. The in vitro uptake of the studied D-g-PNIPAM + Dox nanoparticles into cancer cells was demonstrated by confocal laser scanning microscopy. It was found that D-g-PNIPAM + Dox nanoparticles in contrast to Dox alone showed higher toxicity toward cancer cells. All of the aforementioned facts indicate a possibility of further preclinical studies of the water-soluble D-g-PNIPAM particles’ behavior in animal tumor models in vivo as promising carriers of anticancer agents. Full article
Show Figures

Figure 1

Review

Jump to: Research

19 pages, 2573 KiB  
Review
Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies
by Kamila Butowska, Anna Woziwodzka, Agnieszka Borowik and Jacek Piosik
Materials 2021, 14(9), 2135; https://doi.org/10.3390/ma14092135 - 22 Apr 2021
Cited by 21 | Viewed by 3535
Abstract
Doxorubicin, a member of the anthracycline family, is a common anticancer agent often used as a first line treatment for the wide spectrum of cancers. Doxorubicin-based chemotherapy, although effective, is associated with serious side effects, such as irreversible cardiotoxicity or nephrotoxicity. Those often [...] Read more.
Doxorubicin, a member of the anthracycline family, is a common anticancer agent often used as a first line treatment for the wide spectrum of cancers. Doxorubicin-based chemotherapy, although effective, is associated with serious side effects, such as irreversible cardiotoxicity or nephrotoxicity. Those often life-threatening adverse risks, responsible for the elongation of the patients’ recuperation period and increasing medical expenses, have prompted the need for creating novel and safer drug delivery systems. Among many proposed concepts, polymeric nanocarriers are shown to be a promising approach, allowing for controlled and selective drug delivery, simultaneously enhancing its activity towards cancerous cells and reducing toxic effects on healthy tissues. This article is a chronological examination of the history of the work progress on polymeric nanostructures, designed as efficient doxorubicin nanocarriers, with the emphasis on the main achievements of 2010–2020. Numerous publications have been reviewed to provide an essential summation of the nanopolymer types and their essential properties, mechanisms towards efficient drug delivery, as well as active targeting stimuli-responsive strategies that are currently utilized in the doxorubicin transportation field. Full article
Show Figures

Figure 1

Back to TopTop